We also found that BMI had none or minor effect on bilirubin levels (Table 3), unsupported of an UGT1A1 variants-BMI-bilirubin-NAFLD pathway, a potential confounder for Mendelian randomization trial. The gene discussed is UGT1A1; the disease is metabolic dysfunction-associated steatotic liver disease.